World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 78 17816 16746 8888 8215 417 34681

Neal J. Meropol publications per year

The chart shows the history of publications by Neal J. Meropol between 1981 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Neal J. Meropol published across 45 years, from 1981 to 2025, averaging 9.7 papers a year. Output peaked at 35 publications in 2007. 12 of the 438 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 1981 to 2025. Vertical axis: number of publications, 0 to 35. Peak 35 publications in 2007. 1981: 2 publications 1982: 0 publications 1983: 0 publications 1984: 0 publications 1985: 0 publications 1986: 0 publications 1987: 0 publications 1988: 0 publications 1989: 1 publication 1990: 0 publications 1991: 1 publication 1992: 1 publication 1993: 0 publications 1994: 1 publication 1995: 2 publications 1996: 2 publications 1997: 1 publication 1998: 3 publications 1999: 2 publications 2000: 10 publications 2001: 13 publications 2002: 9 publications 2003: 14 publications 2004: 17 publications 2005: 16 publications 2006: 22 publications 2007: 35 publications 2008: 19 publications 2009: 26 publications 2010: 12 publications 2011: 25 publications 2012: 23 publications 2013: 16 publications 2014: 15 publications 2015: 15 publications 2016: 22 publications 2017: 12 publications 2018: 20 publications 2019: 28 publications 2020: 13 publications 2021: 9 publications 2022: 2 publications 2023: 17 publications 2024: 9 publications 2025: 3 publications
1981 2025

438 publications in total across all disciplines

View publications per year as a table
Neal J. Meropol: publications per year, 1981 to 2025
Year Publications
1981 2
1982 0
1983 0
1984 0
1985 0
1986 0
1987 0
1988 0
1989 1
1990 0
1991 1
1992 1
1993 0
1994 1
1995 2
1996 2
1997 1
1998 3
1999 2
2000 10
2001 13
2002 9
2003 14
2004 17
2005 16
2006 22
2007 35
2008 19
2009 26
2010 12
2011 25
2012 23
2013 16
2014 15
2015 15
2016 22
2017 12
2018 20
2019 28
2020 13
2021 9
2022 2
2023 17
2024 9
2025 3
Total 438
Download as CSV

Neal J. Meropol publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Neal J. Meropol sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 401–420 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 417 publications — 42nd percentile

42% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918 417
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Neal J. Meropol D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Neal J. Meropol sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 78–79 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891 78
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Neal J. Meropol is affiliated with Case Western Reserve University in the United States. Their research primarily spans the field of Medicine, with a substantial focus on Oncology. Their work extends into related subfields including Economics and Econometrics, Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine, and Physiology.

The scientist's research contributions include studies across several cancer-related topics. Main areas of work involve Economic and Financial Impacts of Cancer, Ethics in Clinical Research, Health Systems, Economic Evaluations, Quality of Life, Gastric Cancer Management and Outcomes, Cancer Treatment and Pharmacology, Palliative Care and End-of-Life Issues, and Colorectal Cancer Treatments and Studies.

Neal J. Meropol has authored numerous papers, frequently published in well-known oncology and clinical journals. Notable recent publications include:

  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200, 2023, Journal of Clinical Oncology
  • 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers, 2020, Cancer Research
  • Digital Health Applications in Oncology: An Opportunity to Seize, 2022, JNCI Journal of the National Cancer Institute
  • Prognostic Significance of Patient-Reported Outcomes in Cancer, 2020, JCO Oncology Practice
  • Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts, 2020, Journal of the National Comprehensive Cancer Network

The most frequent venues for their publications include:

  • Journal of Clinical Oncology
  • JCO Oncology Practice
  • JNCI Journal of the National Cancer Institute
  • Cancer Research
  • Journal of the National Comprehensive Cancer Network

Collaborations have been a significant part of their research activities. Frequent co-authors include Maneet Kaur, Smitha Krishnamurthi, Yichen Lu, Jenny S. Guadamuz, and Barry Leybovich.

Best Publications

  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    Bruce J. Giantonio;Paul J. Catalano;Neal J. Meropol;Peter J. O'Dwyer

  • Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

    Fairooz Kabbinavar;Herbert I. Hurwitz;Louis Fehrenbacher;Neal J. Meropol

  • Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

    Leonard B. Saltz;Neal J. Meropol;Patrick J. Loehrer;Michael N. Needle

  • Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

    Shirin Khambata-Ford;Christopher R. Garrett;Neal J. Meropol;Mark Basik

  • American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

    Lowell E. Schnipper;Nancy E. Davidson;Dana S. Wollins;Courtney Tyne

  • Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

    Matthew H. Kulke;Heinz Josef Lenz;Neal J. Meropol;James Posey

  • American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

    Neal J. Meropol;Deborah Schrag;Thomas J. Smith;Therese M. Mulvey

  • Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

    Lowell E. Schnipper;Nancy E. Davidson;Dana S. Wollins;Douglas W. Blayney

  • American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

    Martee L. Hensley;Karen L. Hagerty;Tarun Kewalramani;Daniel M. Green

  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

    S.J. Cohen;C.J.A. Punt;N. Iannotti;B.H. Saidman

  • Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers

    Andrew L. Pecora;Naiyer Rizvi;Gary I. Cohen;Neal J. Meropol

  • American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

    Martee L. Hensley;Lynn M. Schuchter;Celeste Lindley;Neal J. Meropol

  • American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

    Lee M. Ellis;David S. Bernstein;Emile E. Voest;Jordan D. Berlin

  • High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

    B. J. Giantonio;P. J. Catalano;N. J. Meropol;P. J. O'Dwyer

  • Cost of Cancer Care: Issues and Implications

    Neal J. Meropol;Kevin A. Schulman

  • Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

    Anthony W. Tolcher;Monica Mita;Neal J. Meropol;Margaret von Mehren

  • Centralization of Cancer Surgery: Implications for Patient Access to Optimal Care

    Karyn B. Stitzenberg;Elin R. Sigurdson;Brian L. Egleston;Russell B. Starkey

  • Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial

    Brian N. Stein;Nicholas J. Petrelli;Harold O. Douglass;Deborah L. Driscoll

  • UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

    Leslie E. Carlini;Neal J. Meropol;John Bever;Michael L. Andria

  • The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer

    Richard M. Goldberg;Mace L. Rothenberg;Eric Van Cutsem;Al B. Benson

Frequent Co-Authors

Al B. Benson
Al B. Benson Northwestern University
Kevin A. Schulman
Kevin A. Schulman Stanford University
Sharon L. Manne
Sharon L. Manne Rutgers, The State University of New Jersey
Louis M. Weiner
Louis M. Weiner Georgetown University Medical Center
Suzanne M. Miller
Suzanne M. Miller Fox Chase Cancer Center
Cary P. Gross
Cary P. Gross Yale University
Jordan Berlin
Jordan Berlin Vanderbilt University Medical Center
Mary F. Mulcahy
Mary F. Mulcahy Northwestern University
Gary H. Lyman
Gary H. Lyman Fred Hutchinson Cancer Research Center
Michael W. Kattan
Michael W. Kattan Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those exploring alternatives or stepping stones to studying Medicine in the USA, there are numerous online degrees and career pathways that offer flexibility and affordability. Many students begin their healthcare careers through nursing, which has a range of accessible and expedited educational options.

If you’re aiming for advanced practice or leadership roles, an online PhD nursing program allows you to study at the highest academic level from anywhere, often at a fraction of the cost of traditional programs. Those currently working as registered nurses can opt for rn to bsn cheapest programs to enhance credentials and open new career doors.

Non-nurses interested in quickly entering the field should consider cheapest direct entry msn programs. These programs offer accelerated pathways to a master's degree and a new career in nursing. Additionally, aspiring students looking for straightforward admissions can explore direct admit nursing programs, which provide an easier entry point into competitive healthcare education.

Exploring these alternatives ensures prospective students can find a pathway best suited to their career goals, budget, and timeline within the expansive field of healthcare.

Best Scientists Citing Neal J. Meropol

Trending Scientists

Recently Published Articles